Tags

Type your tag names separated by a space and hit enter

Olanzapine versus placebo for out-patients with anorexia nervosa.

Abstract

BACKGROUND

Anorexia nervosa (AN) is a serious psychiatric illness associated with significant morbidity and mortality. There is little empirical support for specific treatments and new approaches are sorely needed. This two-site study aimed to determine whether olanzapine is superior to placebo in increasing body mass index (BMI) and improving psychological symptoms in out-patients with AN.

METHOD

A total of 23 individuals with AN were randomly assigned in double-blind fashion to receive olanzapine or placebo for 8 weeks together with medication management sessions that emphasized compliance. Weight, other physical assessments and measures of psychopathology were collected.

RESULTS

End-of-treatment BMI, with initial BMI as a covariate, was significantly greater in the group receiving olanzapine [F(1, 20)=6.64, p=0.018]. Psychological symptoms improved in both groups, but there were no statistically significant group differences. Of the 23 participants, 17 (74%) completed the 8-week trial. Participants tolerated the medication well with sedation being the only frequent side effect and no adverse metabolic effects were noted.

CONCLUSIONS

This small study suggests that olanzapine is generally well tolerated by, and may provide more benefit than placebo for out-patients with AN. Further study is indicated to determine whether olanzapine may affect psychological symptoms in addition to BMI.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. ea12@columbia.edu

    , , , , ,

    Source

    Psychological medicine 41:10 2011 Oct pg 2177-82

    MeSH

    Adolescent
    Adult
    Analysis of Variance
    Anorexia Nervosa
    Antipsychotic Agents
    Benzodiazepines
    Body Mass Index
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    New York
    Olanzapine
    Ontario
    Outpatients
    Placebos
    Psychiatric Status Rating Scales
    Treatment Outcome
    Weight Gain
    Young Adult

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    21426603

    Citation

    Attia, E, et al. "Olanzapine Versus Placebo for Out-patients With Anorexia Nervosa." Psychological Medicine, vol. 41, no. 10, 2011, pp. 2177-82.
    Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177-82.
    Attia, E., Kaplan, A. S., Walsh, B. T., Gershkovich, M., Yilmaz, Z., Musante, D., & Wang, Y. (2011). Olanzapine versus placebo for out-patients with anorexia nervosa. Psychological Medicine, 41(10), pp. 2177-82. doi:10.1017/S0033291711000390.
    Attia E, et al. Olanzapine Versus Placebo for Out-patients With Anorexia Nervosa. Psychol Med. 2011;41(10):2177-82. PubMed PMID: 21426603.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Olanzapine versus placebo for out-patients with anorexia nervosa. AU - Attia,E, AU - Kaplan,A S, AU - Walsh,B T, AU - Gershkovich,M, AU - Yilmaz,Z, AU - Musante,D, AU - Wang,Y, Y1 - 2011/03/22/ PY - 2011/3/24/entrez PY - 2011/3/24/pubmed PY - 2012/2/18/medline SP - 2177 EP - 82 JF - Psychological medicine JO - Psychol Med VL - 41 IS - 10 N2 - BACKGROUND: Anorexia nervosa (AN) is a serious psychiatric illness associated with significant morbidity and mortality. There is little empirical support for specific treatments and new approaches are sorely needed. This two-site study aimed to determine whether olanzapine is superior to placebo in increasing body mass index (BMI) and improving psychological symptoms in out-patients with AN. METHOD: A total of 23 individuals with AN were randomly assigned in double-blind fashion to receive olanzapine or placebo for 8 weeks together with medication management sessions that emphasized compliance. Weight, other physical assessments and measures of psychopathology were collected. RESULTS: End-of-treatment BMI, with initial BMI as a covariate, was significantly greater in the group receiving olanzapine [F(1, 20)=6.64, p=0.018]. Psychological symptoms improved in both groups, but there were no statistically significant group differences. Of the 23 participants, 17 (74%) completed the 8-week trial. Participants tolerated the medication well with sedation being the only frequent side effect and no adverse metabolic effects were noted. CONCLUSIONS: This small study suggests that olanzapine is generally well tolerated by, and may provide more benefit than placebo for out-patients with AN. Further study is indicated to determine whether olanzapine may affect psychological symptoms in addition to BMI. SN - 1469-8978 UR - https://www.unboundmedicine.com/medline/citation/21426603/full_citation L2 - https://www.cambridge.org/core/product/identifier/S0033291711000390/type/journal_article DB - PRIME DP - Unbound Medicine ER -